These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 29285811)

  • 1. EZH2 overexpression in head and neck cancer is related to lymph node metastasis.
    Nienstedt JC; Schroeder C; Clauditz T; Simon R; Sauter G; Muenscher A; Blessmann M; Hanken H; Pflug C
    J Oral Pathol Med; 2018 Mar; 47(3):240-245. PubMed ID: 29285811
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD151 expression is frequent but unrelated to clinical outcome in head and neck cancer.
    Nienstedt JC; Gröbe A; Lebok P; Büscheck F; Clauditz T; Simon R; Heumann A; Sauter G; Moebius C; Münscher A; Knecht R; Blessmann M; Heiland M; Pflug C
    Clin Oral Investig; 2017 Jun; 21(5):1503-1508. PubMed ID: 27444451
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Up-regulation of enhancer of zeste homolog 2 is associated positively with cyclin D1 overexpression and poor clinical outcome in head and neck squamous cell carcinoma.
    Cao W; Feng Z; Cui Z; Zhang C; Sun Z; Mao L; Chen W
    Cancer; 2012 Jun; 118(11):2858-71. PubMed ID: 21989926
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analyzing simultaneous positive expression of EZH2 and P53 protein to improve predictive value in cervical squamous cell carcinoma.
    Chen SQ; Zhang HM; Li JB; Jiang HY; Fan L; Kong LZ; Yao SZ
    Int J Gynecol Cancer; 2014 Nov; 24(9):1653-8. PubMed ID: 25275664
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High expression of EZH2 is associated with tumor proliferation and prognosis in human oral squamous cell carcinomas.
    Kidani K; Osaki M; Tamura T; Yamaga K; Shomori K; Ryoke K; Ito H
    Oral Oncol; 2009 Jan; 45(1):39-46. PubMed ID: 18619895
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aberrant Epigenetic Regulation in Head and Neck Cancer Due to Distinct EZH2 Overexpression and DNA Hypermethylation.
    Mochizuki D; Misawa Y; Kawasaki H; Imai A; Endo S; Mima M; Yamada S; Nakagawa T; Kanazawa T; Misawa K
    Int J Mol Sci; 2018 Nov; 19(12):. PubMed ID: 30469511
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EZH2 is associated with poor prognosis in head-and-neck squamous cell carcinoma via regulating the epithelial-to-mesenchymal transition and chemosensitivity.
    Chang JW; Gwak SY; Shim GA; Liu L; Lim YC; Kim JM; Jung MG; Koo BS
    Oral Oncol; 2016 Jan; 52():66-74. PubMed ID: 26604082
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Expression of enhancer of zeste homolog 2 in esophageal squamous cell carcinoma and its prognostic value in postoperative patients].
    Wang HR; Wang MH; Lian GY; Wu DG
    Nan Fang Yi Ke Da Xue Xue Bao; 2015 Jan; 35(1):99-102. PubMed ID: 25613619
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aberrant overexpression of EZH2 and H3K27me3 serves as poor prognostic biomarker for esophageal squamous cell carcinoma patients.
    Liu F; Gu L; Cao Y; Fan X; Zhang F; Sang M
    Biomarkers; 2016; 21(1):80-90. PubMed ID: 26631178
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Expression of enhancer of zeste homolog 2 in esophageal squamous cell carcinoma and its prognostic value in postoperative patients].
    Wang H; Wang M; Lian G; Wu D
    Nan Fang Yi Ke Da Xue Xue Bao; 2013 Jan; 33(1):99-102. PubMed ID: 23353165
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Co-expression of Bmi1 and EZH2 as an independent poor prognostic factor in esophageal squamous cell carcinoma.
    Ha SY; Kim SH
    Pathol Res Pract; 2012 Aug; 208(8):462-9. PubMed ID: 22766604
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aberrant expression of EZH2 is associated with a poor outcome and P53 alteration in squamous cell carcinoma of the esophagus.
    Yamada A; Fujii S; Daiko H; Nishimura M; Chiba T; Ochiai A
    Int J Oncol; 2011 Feb; 38(2):345-53. PubMed ID: 21165554
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhancer of zeste homolog 2 (EZH2) promotes progression of cholangiocarcinoma cells by regulating cell cycle and apoptosis.
    Nakagawa S; Okabe H; Sakamoto Y; Hayashi H; Hashimoto D; Yokoyama N; Sakamoto K; Kuroki H; Mima K; Nitta H; Imai K; Chikamoto A; Watanabe M; Beppu T; Baba H
    Ann Surg Oncol; 2013 Dec; 20 Suppl 3():S667-75. PubMed ID: 23887863
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Polycomb repressive complex 2 and its core component EZH2: potential targeted therapeutic strategies for head and neck squamous cell carcinoma.
    Cheng Y; Song Z; Fang X; Tang Z
    Clin Epigenetics; 2024 Apr; 16(1):54. PubMed ID: 38600608
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dysregulation of the repressive H3K27 trimethylation mark in head and neck squamous cell carcinoma contributes to dysregulated squamous differentiation.
    Gannon OM; Merida de Long L; Endo-Munoz L; Hazar-Rethinam M; Saunders NA
    Clin Cancer Res; 2013 Jan; 19(2):428-41. PubMed ID: 23186778
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overexpression of enhancer of zeste homolog 2 (EZH2) characterizes an aggressive subset of prostate cancers and predicts patient prognosis independently from pre- and postoperatively assessed clinicopathological parameters.
    Melling N; Thomsen E; Tsourlakis MC; Kluth M; Hube-Magg C; Minner S; Koop C; Graefen M; Heinzer H; Wittmer C; Sauter G; Wilczak W; Huland H; Simon R; Schlomm T; Steurer S; Krech T
    Carcinogenesis; 2015 Nov; 36(11):1333-40. PubMed ID: 26392259
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting EZH2 regulates tumor growth and apoptosis through modulating mitochondria dependent cell-death pathway in HNSCC.
    Zhou X; Ren Y; Kong L; Cai G; Sun S; Song W; Wang Y; Jin R; Qi L; Mei M; Wang X; Kang C; Li M; Zhang L
    Oncotarget; 2015 Oct; 6(32):33720-32. PubMed ID: 26378043
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overexpression of YB1 and EZH2 are associated with cancer metastasis and poor prognosis in renal cell carcinomas.
    Wang Y; Chen Y; Geng H; Qi C; Liu Y; Yue D
    Tumour Biol; 2015 Sep; 36(9):7159-66. PubMed ID: 25877750
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhancer of zeste homolog 2 expression is associated with metastasis and adverse clinical outcome in clear cell renal cell carcinoma: a comparative study and review of the literature.
    Xu B; Abourbih S; Sircar K; Kassouf W; Mansure JJ; Aprikian A; Tanguay S; Brimo F
    Arch Pathol Lab Med; 2013 Oct; 137(10):1326-36. PubMed ID: 24079759
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aberrant expression of EZH2 is associated with pathological findings and P53 alteration.
    Shiogama S; Yoshiba S; Soga D; Motohashi H; Shintani S
    Anticancer Res; 2013 Oct; 33(10):4309-17. PubMed ID: 24122997
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.